Pricing Log in Create free account

Biogen Inc. (BIIB) vs Grifols, S.A. (GRFS)

Biogen Inc. and Grifols, S.A. are both Drug Manufacturers General companies. Biogen Inc. is the larger, with a market value of $36.1B against $2.2B — 16.5× the size. Grifols, S.A. trades at the lower P/E: 18.2× against 105×. Grifols, S.A. grew revenue faster over the last twelve months: 10.9% against 2.30%. Grifols, S.A. has the higher net margin (6.02% vs 3.37%) and the higher return on invested capital (4.76% vs 1.94%). Across the 22 metrics below, Grifols, S.A. leads on 18 and Biogen Inc. on 4.

Valuation

Metric BIIB GRFS Drug Manufacturers General median
P/E 105.24 18.23 26.51
P/S 3.57 0.65 3.49
P/B 1.94 0.60 5.28
Price to free cash flow 21.67 7.65 21.67
EV/EBITDA 18.65 8.40 14.73
EV/Sales 4.15 1.77 4.15
Earnings yield 0.95% 5.49% 2.41%
Free cash flow yield 4.61% 13.08% 4.07%

Profitability

Metric BIIB GRFS Drug Manufacturers General median
Gross margin 73.96% 37.55% 73.01%
Operating margin 7.53% 16.69% 18.34%
Net margin 3.37% 6.02% 7.31%
Free cash flow margin 16.45% 8.51% 18.56%
Return on equity 1.87% 5.80% 5.80%
Return on assets 1.13% 2.28% 2.28%
Return on invested capital 1.94% 4.76% 6.26%

Growth

Metric BIIB GRFS Drug Manufacturers General median
Revenue growth (TTM) 2.30% 10.87% 6.72%
EPS growth (last fiscal year) (21.38%) 168.00% 21.81%
Revenue growth, 5-year CAGR (5.96%) 6.89% 4.75%
Net income growth, 5-year CAGR (20.22%) (8.43%) 0.00%

Health

Metric BIIB GRFS Drug Manufacturers General median
Debt to equity 0.39 1.12 0.62
Current ratio 1.95 2.33 1.39
Net debt to EBITDA 0.84 5.19 1.15

Dividend

Metric BIIB GRFS Drug Manufacturers General median
Dividend yield — 1.12% 2.32%
Payout ratio — 0.20 0.59

Size

Metric BIIB GRFS Drug Manufacturers General median
Market cap 36.06b 2.18b 129.04b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack